D D Bigner
About
In The Last Decade
D D Bigner
14 papers receiving 505 citations
Peers
Comparison fields: 5 of 65
- Molecular Biology 283
- Genetics 226
- Oncology 157
- Pulmonary and Respiratory Medicine 115
- Cancer Research 85
Countries citing papers authored by D D Bigner
This map shows the geographic impact of D D Bigner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D D Bigner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D D Bigner more than expected).
Fields of papers citing papers by D D Bigner
This network shows the impact of papers produced by D D Bigner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D D Bigner. The network helps show where D D Bigner may publish in the future.
Co-authorship network of co-authors of D D Bigner
This figure shows the co-authorship network connecting the top 25 collaborators of D D Bigner. A scholar is included among the top collaborators of D D Bigner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D D Bigner. D D Bigner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 27 | |
| 2 | 14 | |
| 3 | 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. | 50 |
| 4 | Treatment of neoplastic meningitis with intrathecal temozolomide. | 29 |
| 5 | 160 | |
| 6 | Analysis of DNA mismatch repair proteins in human medulloblastoma. | 10 |
| 7 | Activity of temozolomide in the treatment of central nervous system tumor xenografts. | 124 |
| 8 | Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. | 7 |
| 9 | Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. | 18 |
| 10 | The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma. | 15 |
| 11 | Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR. | 3 |
| 12 | 16 | |
| 13 | Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. | 22 |
| 14 | Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. | 23 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.